Cowen and Company’s Zymeworks ZYME Stock Holding History

Cowen and Company’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-35,000	Closed	-$85K	–	650
2020 Q4	$85K	Buy	+35,000	New	+$1.63M	0.01%	235

Other funds holding ZYME

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BNP Paribas Asset Management

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Cowen and Company's ZYME Position: Q3 2022 in Review

Cowen and Company sold out of Zymeworks (ZYME) in Q3 2022, closing a stake of 1,500,000 shares — an estimated $7.95M sold.

Cowen and Company first reported a position in ZYME in Q2 2022 and held it in 1 quarter. The position peaked at $7.95M in Q2 2022. 91 funds tracked by Wall St. Rank hold ZYME as of Q3 2022.

Cowen and Company reported no remaining Zymeworks position as of Q3 2022 after selling out during the quarter.
Cowen and Company sold 1,500,000 Zymeworks shares in Q3 2022, an estimated $7.95M.
Cowen and Company first reported a position in Zymeworks in Q2 2022 and held it in 1 quarter.
Cowen and Company's Zymeworks position peaked at $7.95M in Q2 2022.
91 funds tracked by Wall St. Rank held Zymeworks as of Q3 2022.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.